Catheter based intracoronary brachytherapy leads to increased platelet activation

M Jaster, V Fuster, P Rosenthal, M Pauschinger, Q-V Tran, D Janssen, W Hinkelbein, P Schwimmbeck, H-P Schultheiss, U Rauch

Background: Vascular brachytherapy (VBT) after percutaneous coronary intervention (PCI) is associated with a higher risk of stent thrombosis than conventional treatment.

Objective: To investigate in vivo periprocedural platelet activation with and without VBT, and to assess a possible direct effect of radiation on platelet activation.

Design: Of 50 patients with stable angina, 23 received VBT after PCI, while 27 had PCI only. The 23 patients who received VBT after PCI were pretreated for one month with aspirin and clopidogrel. Platelet activation was assessed by flow cytometry.

Results: The two patient groups did not differ in their platelet activation before the intervention. There was a significant increase in activation immediately after VBT, with 21.2% (interquartile range 13.0% to 37.6%) thrombospondin positive and 54.0% (42.3% to 63.6%) CD 63 positive platelets compared with 12.7% (9.8% to 14.9%) thrombospondin positive and 37.9% (33.2% to 45.2%) CD 63 positive platelets before the intervention. Patients without VBT had no periprocedural difference in platelet activation immediately after PCI. No increase in platelet activation was found after ex vivo irradiation of blood samples obtained from healthy controls.

Conclusions: Catheter based intracoronary VBT carried out according to current standards is highly thrombogenic. The current antithrombotic treatment with aspirin and clopidogrel is not sufficient to suppress platelet activation during the procedure. From in vitro experiments, it appears that platelet activation during brachytherapy is not caused by irradiation but by the procedure of catheter based VBT.

Percutaneous coronary interventions (PCI) now include more than one million stent implantations worldwide each year. Stent implantation has been shown to reduce the risk of restenosis by eliminating vascular contraction. However, stents do not inhibit neointimal proliferation but tend to induce it more than other devices. In-stent restenosis is a major limitation of intracoronary stent implantation and affects approximately 300,000 patients worldwide each year. The rate of restenosis caused by neointimal proliferation is still high, ranging from 15–50% depending on the type of lesion treated. There is a higher incidence of recurrent restenosis after PCI for in-stent restenosis.

A new treatment strategy using ionising radiation for preventing recurrent in-stent restenosis after PCI is catheter based intracoronary β radiation (vascular brachytherapy, VBT). In large clinical trials, both β and γ radiation have proven effective in reducing restenosis. This new treatment is followed by an increased number of adverse events such as subacute and late thrombosis, but the mechanism of the increase in thrombotic events after VBT is not yet well understood. Platelet activation has been identified as an independent risk factor for acute and subacute ischaemic events after PCI. These thrombotic occlusions are associated with increased mortality. The increased incidence of subacute and late adverse events after brachytherapy reflects its high thrombogenicity, which cannot be completely suppressed by current antiplatelet drugs, especially after new stent placement.

Our study aimed to investigate whether brachytherapy with β radiation emitted by 90Sr/90Y source trains leads to higher platelet activation than PCI without radiation. We also carried out in vitro experiments on whole blood, applying high and low dose radiation to assess a possible direct effect of irradiation on platelet activation and blood thrombogenicity.

METHODS

Patients
The study included 50 patients with stable angina, 23 of whom (mean (SD) age, 61 (9) years; 19 men, four women) were treated with the Novoste Beta-Cath system for in-stent restenosis after successful primary intervention. Twenty seven patients (58 (9) years; 23 men, four women) who underwent PCI without irradiation served as controls. Brachytherapy and control patients did not differ significantly in age, sex, distribution of coronary risk factors, or number of diseased vessels (table 1). Non-ionic contrast medium was used in all patients (Ultravis 370, Schering, Berlin, Germany). The left circumflex artery was treated more often in controls.

The radioactive source used was 90Sr/90Y, a β emitter with a maximum energy of 2.27 MeV. All irradiated patients were treated with the same source trains between March and October 2000 after informed written consent and approval by the local ethics committee. Radiation doses were 18.4, 23.0, or 25.3 Gy, depending on the major vessel diameter accessed by intravascular ultrasound (IVUS) (table 2). We used two different source trains: one device 40 mm long with 16 active encapsulated seeds and the other 60 mm long with 24 seeds.

**Abbreviations:** FITC, fluorescein isothiocyanate; IVUS, intravascular ultrasound; PCI, percutaneous coronary intervention; TSP, thrombospondin; VBT, vascular brachytherapy
Brachytherapy and blood thrombogenicity

Table 1 Clinical details of the patients and controls

<table>
<thead>
<tr>
<th></th>
<th>Patients treated with brachytherapy (n = 23)</th>
<th>Patients treated without irradiation (n = 27)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>61 (9)</td>
<td>58 (9)</td>
</tr>
<tr>
<td>Sex (F/M)</td>
<td>4/19</td>
<td>4/23</td>
</tr>
<tr>
<td>Treated coronary artery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LAD</td>
<td>12/23</td>
<td>11/27</td>
</tr>
<tr>
<td>LCx</td>
<td>1/23</td>
<td>9/27</td>
</tr>
<tr>
<td>RCA</td>
<td>10/23</td>
<td>7/27</td>
</tr>
<tr>
<td>Number of diseased arteries</td>
<td>1.9 (0.8)</td>
<td>2.2 (0.7)</td>
</tr>
<tr>
<td>Smoking</td>
<td>14/23</td>
<td>16/27</td>
</tr>
<tr>
<td>Diabetes</td>
<td>5/23</td>
<td>7/27</td>
</tr>
<tr>
<td>Hypertension</td>
<td>12/23</td>
<td>13/27</td>
</tr>
<tr>
<td>Lipids</td>
<td>20/23</td>
<td>22/27</td>
</tr>
<tr>
<td>Family history</td>
<td>1/23</td>
<td>2/27</td>
</tr>
<tr>
<td>ACT of the procedure (s)</td>
<td>359 (64)</td>
<td>342 (67)</td>
</tr>
</tbody>
</table>

Values are mean (SD) or n. *p*<0.05
ACT, activated clotting time; LAD, left anterior descending coronary artery; LCx, left circumflex artery; RCA, right coronary artery.

Table 2 Comparison of the different source trains used in our study between March and September 2000

<table>
<thead>
<tr>
<th>Patients treated with different train doses (n)</th>
<th>40 mm source train</th>
<th>60 mm source train</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.4 Gy</td>
<td>19/23</td>
<td>4/23</td>
</tr>
<tr>
<td>23.0 Gy</td>
<td>7/19</td>
<td>0/4</td>
</tr>
<tr>
<td>25.3 Gy</td>
<td>6/19</td>
<td>2/4</td>
</tr>
<tr>
<td>39.3 Gy</td>
<td>6/19</td>
<td>2/4</td>
</tr>
</tbody>
</table>

The dose rate varies for each source train and depends on the time of radioactivity storage.

The dose rate at the target point 2 mm away from the centre of the source train was determined to be 0.1VGy/s for the 40 mm source train and 0.08 Gy/s for the 60 mm source train, with a longer radiation time to achieve an equal dose. No new stent placement was undertaken during brachytherapy.

All patients treated with brachytherapy received dual antiplatelet treatment with aspirin and an ADP receptor antagonist (clopidogrel 300 mg loading dose followed by 75 mg per day) three to four weeks before and at least six months after elective irradiation. No pretreatment was given in the control group. Control patients were treated with aspirin and additionally received an ADP receptor antagonist for two weeks after the intervention only in cases of stent implantation (12/27) or stent angioplasty (5/27). No glycoprotein IIb/IIIa receptor antagonist was used in any of the cases.

Blood samples were taken before and immediately after the intervention in the catheter laboratory, during effective heparinisation and before the removal of the venous sheath in all patients. The blood was analysed immediately. Blood samples after 24 hours were taken the next morning before breakfast.

IVUS

Intravenous heparin was given to obtain a target activated clotting time (ACT) of 300 seconds. Intravascular ultrasound (Endosonics) was carried out in irradiated patients to confirm a significant in-stent restenosis—that is, more than 50% cross sectional area. Stent malposition or underexpansion was excluded as the cause of the angiographically visualised in-stent restenosis. A motorised pull back procedure was applied at 1 mm/s. After balloon angioplasty, IVUS was done to confirm a residual stenosis with a lumen diameter of less than 30%. The elastica externa was assessed as the vessel diameter containing the target cells for irradiation.

Platelet activation measurement

Whole blood was collected in a special sample medium (containing EDTA, hydroxychloroquine sulfate, sodium hydroxide, and heparin sodium) through a 1 mm Wassermann cannula without a tourniquet and immediately fixed in paraformaldehyde (1%). Platelet activation was determined by flow cytometry as described. In short, platelet-rich plasma was obtained by centrifugation at 100 g for 10 minutes (room temperature). Platelets were counted and diluted with phosphate buffered saline to a final concentration of 1000/µl. Aliquots were incubated with saturated concentrations of monoclonal antibodies against the activation dependent activation markers CD 63 and thrombospondin and the constitutively expressed glycoprotein IIb/IIIa. A second FITC labelled anti-mouse antibody was added to detect the primary antibodies. Flow cytometry was then carried out, with 10 000 events acquired for each sample. Data are given as the percentage of marker positive platelets for thrombospondin and CD 63 or as the mean immunofluorescence intensity for glycoprotein IIb/IIIa.

Ex vivo radiation experiments

Blood samples were obtained from healthy subjects without a tourniquet and immediately mixed with citrate. Whole blood was divided into aliquots, one serving as a control and the others being irradiated. Two different doses (20 Gy and 160 Gy) were used in repeated experiments to cover the dose range applied to blood in patients undergoing brachytherapy. A linear accelerator with a 6 or 18 MeV photon beam served as the radiation source. Immediately after irradiation, which took about 15 minutes, all aliquots were fixed in 1% paraformaldehyde and analysed by flow cytometry as above.

Statistics

If data were normally distributed, Student’s t test was used to compare continuous variables. Results are expressed as mean (SD). If data were not normally distributed, we used Wilcoxon’s rank test to compare continuous variables. Results are expressed as medians and interquartile ranges. Binary variables were compared using the χ² test or Fisher’s exact test when appropriate. The Mann-Whitney U test was chosen to compare different groups. A probability value of p < 0.05 in the two sided test was considered significant.
Table 3 Platelet activation in patients treated with and without vascular brachytherapy

<table>
<thead>
<tr>
<th></th>
<th>Treated with VBT</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>% TSP positive platelets in blood before the intervention</td>
<td>12.7 (9.8 to 14.9)</td>
<td>10.9 (8.8 to 14.1)</td>
</tr>
<tr>
<td>% TSP positive platelets in blood after the intervention</td>
<td>21.2 (13.0 to 37.6)</td>
<td>9.2 (7.4 to 10.1)</td>
</tr>
<tr>
<td>% CD 63 positive platelets in blood before the intervention</td>
<td>37.9 (33.2 to 45.2)</td>
<td>46.3 (33.7 to 51.3)</td>
</tr>
<tr>
<td>% CD 63 positive platelets in blood after the intervention</td>
<td>54.0 (42.3 to 63.6)</td>
<td>41.2 (34.1 to 49.8)</td>
</tr>
<tr>
<td>GP IIb/IIIa on platelet surface before the intervention</td>
<td>305.7 (269.5 to 381.2)</td>
<td>309.3 (276.9 to 365.4)</td>
</tr>
<tr>
<td>GP IIb/IIIa on platelet surface after the intervention</td>
<td>299.7 (263.1 to 377.4)</td>
<td>301.0 (261.7 to 384.7)</td>
</tr>
</tbody>
</table>

Platelet activation is indicated by the median and interquartile range of TSP positive and CD 63 positive platelets before and after the intervention.

Ex vivo experiments

Irradiation of blood samples (not platelet-rich plasma) with target doses used in humans did not affect platelet activation. Even eight times higher doses did not increase platelet activation compared with the non-irradiated control aliquots (table 4). This indicates that platelet activation is not directly affected by irradiation.

DISCUSSION

This study is the first to show that platelet activation is increased by the brachytherapy currently applied in clinical practice. A notable increase was found after brachytherapy compared with PCI without irradiation. We have previously identified increased platelet activation after conventional PCI as an independent risk factor for acute ischaemic events. The data on radiation delivery devices submitted for US Food and Drug Administration (FDA) approval showed that patients treated with radiation benefit from a reduction in recurrent stenosis but also have the disadvantage of an increased rate of thrombotic events. Thrombotic occlusions are associated with increased mortality after PCI and an increased risk of myocardial infarctions after...
The increase in platelet activation after brachytherapy is not suppressed by concomitant treatment with aspirin and clopidogrel. Both drugs were given to all 23 patients three to four weeks before elective brachytherapy. In the group of control patients, only those with PCI for in-stent restenosis or new stent implantation received ADP receptor antagonists in addition to aspirin. In these control patients, treatment with an ADP receptor antagonist started during the intervention. Control patients showed no change in platelet activation after the intervention. The results coincide with previous reports on periprocedural platelet activation in stable angina patients treated with PCI. The differences in treatment with an ADP receptor antagonist started during effective heparinisation. A possible effect of heparinisation on platelet activation cannot be excluded. However, during prolonged and severe platelet activation. Despite pretreatment with aspirin and clopidogrel for three to four weeks, platelet activation—as found for TSP and CD 63—increased during intracoronary brachytherapy. The more intense pretreatment with thienopyridines in the brachytherapy group makes the results even more striking.

Our results support the discussion of three different mechanisms for increased platelet reactivity after VBT: first, the irradiation itself affects in vivo platelet activation and blood thrombogenicity; second, the currently used catheter based radiation source trains and their time consuming procedures may be highly thrombogenic; and third, VBT affects platelet activation indirectly owing to endothelial damage. Nitric oxide/endothelium derived relaxing factor (NO/EDRF) produced by the intact endothelium inhibits platelet activation. This endothelium derived antithrombotic effect may be reduced after VBT.

We undertook in vitro experiments to rule out a direct effect of irradiation on platelet activation. The doses used were biologically equivalent to those delivered by the radioactive sources. There was no direct radiation dependent effect on platelet activation in these in vitro experiments (table 4). The findings coincide with previous reports on short term irradiation in doses of up to 150 Gy. It remains to be shown whether the degree of platelet activation is determined by the procedure of catheter based intracoronary brachytherapy or by the effects of VBT on endothelial function. Platelet activation may be influenced by the length of the source train correlating with the ending data rate and the indwelling time of the highly thrombogenic catheter based delivery system in the coronary artery. However, it can also be hypothesised that the negative impact of VBT on endothelial function may affect platelet reactivity after intracoronary brachytherapy.

Recent reports on VBT in patients receiving combined antiplatelet treatment (aspirin plus ADP receptor antagonist) showed an increased rate of subacute thrombosis after PCI with irradiation compared with stenting without VBT. Our data showed that platelet activation after intracoronary brachytherapy was only incompletely suppressed by antiplatelet treatment with aspirin and clopidogrel. The second blood samples were taken immediately after the intervention during effective heparinisation. A possible effect of heparinisation on platelet activation cannot be excluded. However, all patients received heparin, so the groups remain comparable and the increase in platelet activation was found in the VBT group only.

Increased platelet reactivity after brachytherapy may trigger acute and subacute stent thrombosis after VBT and increase the number of myocardial infarcts, especially after new stent placement during VBT. In an analysis of 473 patients with in-stent restenosis enrolled in various VBT protocols, subacute thrombosis occurred in three patients (0.9%) treated with VBT and in none of the placebo treated patients. The acute changes in platelet activation observed here cannot be related to alterations in platelet reactivity or thrombotic events found three to six months after VBT (late thrombosis). Factors to be considered in connection with late thrombosis are the damaged endothelium and thrombogenic vasculature at the site of injury where re-endothelialisation is delayed or fails to occur after irradiation.31-32

Conclusions

Platelet activation is increased after catheter based VBT compared with PCI without irradiation. This increase occurs despite aggressive antiplatelet treatment with aspirin and clopidogrel given for three to four weeks before brachytherapy. Our in vitro experiments did not show a direct effect of irradiation on platelets and indicated that catheter based VBT involving endothelial damage is a highly thrombogenic procedure.

References


A 38 year old woman with acute chest pain was admitted to the hospital. Positive troponins and electrocardiographic signs of anterior wall myocardial infarction during atrial fibrillation were found. Echocardiography (panel below) showed hypokinesia of the anterior wall and severe mitral stenosis (arrowhead; LV, left ventricle; SC, spontaneous contrast). Coronary angiography showed an occlusion of the mid left anterior descending artery (LAD) (panel A, upper row). Using the Guardwire Plus system (Medtronic Inc), the wire was positioned in the distal LAD and three aspirations during distal balloon inflation were performed resulting in complete reperfusion (TIMI-III flow) (panel B, upper row) of an angiographically normal appearing LAD (arrow) and normalisation of ST-T segments. The retrieved debris, a large irregular shaped particle (panel A, lower row, arrow), was histopathologically analysed and showed predominantly thrombus (T) with small but non-atherosclerotic parts of vascular media (M) and intima (I) (panel B, lower row, Mason’s tri-chrome). An additional stain for inflammation showed that CD68 positive macrophages within this part of the retrieved intima were absent, suggesting absence of atherosclerotic coronary disease. It was hypothesised that the occlusion was due to a significant embolus derived from a prominent thrombus (arrow) found in the left atrial appendage as seen on transoesophageal echocardiography. Also massive spontaneous contrast (SC) was visualised in the left atrium. We suspect that the media and intima found in the aspirate were most likely obtained following traumatic passage of the aspiration catheter. The patient afterwards underwent mitral valve surgery as well as removal of the intra-atrial thrombus, and recovered well.

J Van der Heyden
S Verheyen
P Vermeersch
janenvan@hotmail.com
Ruptured plaque or embolised thrombus

J Van der Heyden, S Verheye and P Vermeersch

*Heart* 2004 90: 164
doi: 10.1136/hrt.2003.020164

Updated information and services can be found at:
http://heart.bmj.com/content/90/2/164

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/